A national gatekeeper by design
Norway’s approach to health technology adoption is distinctive not because it values evidence all modern health systems do but because it insists on confronting the system consequences of evidence before scale, not after. That responsibility sits with New Methods (Nye metoder), the mandatory national framework that determines which technologies enter specialist care, how they are used, and under what conditions they are paid for. https://www.nyemetoder.no/metoder/kontinuerlig-glukosemaling-og-flash-glukosemaling-indikasjon-ii/
What makes New Methods unusual is its refusal to treat adoption as a local experiment. In many countries, hospitals test new technologies first, utilisation grows organically, and reimbursement logic is forced to catch up later. Norway reverses that sequence. Evidence is assessed centrally. Organisational impact is modelled explicitly. Workforce demand, follow-up intensity, and long-term budget exposure are treated as economic variables, not implementation details. Only then is access defined.
This is not a system designed to reward speed. It is designed to prevent momentum from masquerading as value.
At its core lies a sober economic insight, borne out repeatedly in the Norwegian literature on unwarranted variation and low-value care: health systems rarely fail because innovation is absent. They fail because adoption outpaces capacity — because technologies diffuse faster than staffing, governance, and clinical pathways can adapt. New Methods exists to slow that process deliberately, forcing the health system to price not just the technology, but the behaviour it will induce.
In Norway, innovation is not assumed to be benign. It must first prove that the system can live with it.
When New Methods applies and when it doesn’t
New Methods applies not when a technology is new, but when it matters to the system. Specifically, it is triggered whenever an innovation is likely to create ongoing obligations for the specialist health service: recurring costs, changes in clinical pathways, shifts in referral behaviour, or pressure for nationally uniform access.
That scope is deliberately broad. It captures medicines, medical devices, diagnostics, and an expanding category of digital and data-driven tools whose impact lies less in their unit price than in how they reorganise care. The decisive question is not whether a technology is innovative or evidence-backed, but whether its use would ultimately fall to the regional health authorities to fund, staff, and manage. If it would, the case belongs in New Methods.
What New Methods does not cover is equally instructive. Primary care sits outside its remit, as does purely private activity. This is not an oversight. It reflects a clear boundary in Norway’s health governance: the system intervenes most forcefully at the point where public specialist capacity becomes the limiting factor. That is where utilisation, workforce strain, and long-term cost exposure converge and where uncontrolled adoption does the most damage.
In Norway, regulation follows responsibility. Where the public system carries the risk, it also claims the right to decide.
Entry into the system: getting onto the national agenda
Entry into New Methods does not begin with a dossier. It begins with a judgement call. Access is initiated through a proposal to the Bestillerforum for Nye Metoder, the body that decides whether a technology warrants national scrutiny at all.
At this stage, the system is not asking for polished cost-effectiveness models or international adoption stories. It is asking a more fundamental question: is this a problem that Norway should decide once, centrally, rather than letting hospitals improvise their own answers?
What matters, therefore, is not how comprehensive the evidence file is, but whether the technology raises issues that cannot be safely resolved at the local level:
- Does it redefine what counts as standard care?
- Does it create new patterns of monitoring, follow-up, or specialist involvement?
- Does endorsement risk rapid uptake before consequences are fully understood?
- Would the absence of a national position predictably lead to regional variation?
These are governance questions, not scientific ones and they are treated as such.
Proposals most often come from clinicians or health authorities, sometimes with industry support in the background. But credibility here is earned clinically, not commercially. Without a trusted clinical signal that the issue is real and system-relevant, technologies rarely advance beyond this point.
In Norway, the first hurdle is not proof that something works. It is proof that the system needs to take responsibility for deciding whether — and how — it should be used at all.
Assessment as economic control, not academic exercise
Once commissioned, assessment is usually carried out by the Norwegian Medical Products Agency or another national body. This is where Norway’s philosophy becomes most visible.
Clinical effectiveness is assessed, but it is not privileged above other concerns. Economic modelling, organisational impact, and workforce implications are treated as equally material. A technology that improves outcomes but increases demand for scarce specialist staff may be judged unaffordable even if its unit cost is modest.
This logic mirrors findings in the Norwegian and international literature on low-value care: that utilisation growth, not price alone, is the dominant driver of long-term cost pressure. As the BMJ Open Quality evidence shows, unwarranted variation persists even in publicly funded systems unless adoption is actively governed.
Assessment therefore takes time often two years or more. This is not bureaucratic drift. It is an explicit trade-off between speed and control.
What “completion” means and what it doesn’t
When an assessment is finalised and formally signed off, the evidence phase ends but access is still undecided. Responsibility shifts to the four Regional Health Authorities, who prepare the case for the Decision Forum.
This distinction matters. Health technology assessment in Norway does not confer entitlement. It provides a structured basis for a coverage decision, where severity, benefit, cost-effectiveness, and system capacity are weighed explicitly.
This separation between assessment and decision is one reason Norway’s system resists political or commercial pressure. Evidence informs decisions but does not dictate them.
Decisions are conditional by default
Very few technologies emerge from New Methods with unrestricted access. More commonly, approval comes with conditions:
- access limited to defined patient subgroups,
- use restricted to specialist settings,
- requirements for follow-up, monitoring, or staffing,
- or volume controls designed to prevent rapid expansion.
These conditions are not compromises. They are the mechanism by which Norway reconciles innovation with finite capacity. The system is designed to let technologies in narrowly first and expand only if real-world use confirms value without destabilising care delivery.
Re-assessment: when the system reopens the file
Crucially, New Methods also includes a formal mechanism for re-assessment (revurdering). This allows decisions to be revisited when the evidence landscape changes for example through new survival data, altered clinical practice, or shifts in comparator standards.
Re-assessment is rare and procedural, not political. Its existence signals that Norway’s system is conservative, but not static. Decisions are durable, yet revisable when justified.
In economic terms, this treats coverage as a contingent contract, not a permanent entitlement.
What the system rewards
For those seeking access to the Norwegian health system, the lesson is consistent across cases and technologies.
New Methods rewards:
- precise clinical positioning,
- credible estimates of eligible populations,
- realistic assumptions about adherence and follow-up,
- and early acknowledgement of workforce constraints.
What it resists are broad population claims and promises that the system will “adapt later”. In Norway, adaptation must be designed in advance.
The economic logic underneath it all
Seen from the outside, New Methods can appear slow and restrictive. Seen from within, it reflects a coherent economic worldview: that the most expensive part of healthcare is not technology, but the behaviour it induces.
By forcing technologies to justify not only their clinical benefit, but their organisational footprint, Norway has built a system that trades speed for sustainability. It is a model less concerned with being first, and more concerned with being able to live with its decisions.
For innovators, clinicians, and policymakers, understanding how to work with New Methods is therefore not about learning a process. It is about understanding a philosophy: that in a capacity-constrained health system, access must be earned carefully, conditionally, and in full view of its consequences.
A live example: CGM in type 2 diabetes
The New Methods case for continuous and flash glucose monitoring in insulin-treated type 2 diabetes makes this logic visible in real time. The proposal entered the system in mid-2023 and proceeded to a full national assessment, covering not only clinical outcomes but long-term economics and organisational impact. By January 2026, the Norwegian Medical Products Agency had completed its evaluation, and Bestillerforum for Nye Metoder formally closed the assessment and passed it to the regional health authorities for decision preparation.
What is striking is not just the length of the process, but what happened while it was under way. During the assessment period, the system introduced a temporary group exemption, allowing limited use of CGM for selected patients in specialist care. This was not an endorsement in advance of evidence, but a controlled accommodation of clinical need while the economic and organisational consequences were still being worked through.
The message is unmistakable. In Norway, even widely used technologies are not allowed to diffuse unchecked. Access can be granted narrowly, provisionally, and reversibly — while the system decides whether it can afford not just the device, but the follow-up, staffing, and utilisation patterns it brings with it.
References
Nye Metoder (Norwegian National System for Managed Introduction of New Health Technologies)
Nye Metoder (2025) Velkommen til Nye metoder. Available at: https://www.nyemetoder.no (Accessed: 6 February 2026).
Foundational source describing the governance structure, decision criteria, and national role of New Methods in specialist healthcare.
Nye Metoder – Method case: Continuous and flash glucose monitoring in type 2 diabetes
Nye Metoder (2026) Kontinuerlig glukosemåling og flash glukosemåling – indikasjon II (ID2023_075). Available at:
https://www.nyemetoder.no/metoder/kontinuerlig-glukosemaling-og-flash-glukosemaling-indikasjon-ii/
(Accessed: 6 February 2026).
Primary government record illustrating how New Methods operates in practice: timelines, HTA commissioning, group exemptions, and transition to decision-making.
Norwegian Medical Products Agency (HTA report)
Norwegian Medical Products Agency (2026) Continuous glucose monitoring in insulin-treated type 2 diabetes: A health technology assessment. Oslo: Direktoratet for medisinske produkter.
Demonstrates Norway’s emphasis on long-term modelling, workforce impact, adherence, and organisational consequences — not just clinical endpoints.
Tjomsland, O. et al. (2025)
Tjomsland, O., Bertilsson, H.M., Bjerkan, G. et al. (2025) ‘Protocol for a national intervention programme aimed to reduce unwarranted variation and overuse of shoulder arthroscopy in Norway’, BMJ Open Quality, 14, e003099.
https://doi.org/10.1136/bmjoq-2024-003099
Key peer-reviewed evidence explaining Norway’s intolerance of uncontrolled diffusion, unwarranted variation, and low-value care — the intellectual backbone of New Methods.
Norwegian Institute of Public Health (HTA role)
Folkehelseinstituttet (FHI) (2023) Health technology assessment in Norway. Oslo: Norwegian Institute of Public Health.
Explains the HTA methodology used within New Methods and the separation between evidence assessment and coverage decision-making.
OECD (Health system governance)
OECD (2023) Value for Money in Health Spending. Paris: OECD Publishing.
https://doi.org/10.1787/3a23c1a0-en
International context supporting Norway’s emphasis on system capacity, workforce constraints, and utilisation control over unit-cost optimisation.
Sutherland, K. and Levesque, J.-F. (2020)
Sutherland, K. and Levesque, J.-F. (2020) ‘Unwarranted clinical variation in health care: Definitions and proposal of an analytic framework’, Journal of Evaluation in Clinical Practice, 26(3), pp. 687–696.
Foundational framework cited repeatedly in Norwegian policy literature to justify national control of variation and adoption.
Siemieniuk, R.A.C. et al. (2017)
Siemieniuk, R.A.C. et al. (2017) ‘Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline’, BMJ, 357, j1982.
Illustrates the long lag between evidence and de-implementation — a key rationale for Norway’s pre-emptive governance model.
Danielsen, E. et al. (2023)
Danielsen, E., Gulati, S., Salvesen, Ø. et al. (2023) ‘Clinical outcomes after surgery performed in public and private hospitals: a nationwide relative effectiveness study’, Bone & Joint Journal, 105-B, pp. 64–71.
Supports Norway’s concern that provider type and incentives materially affect utilisation and outcomes — informing national rather than local decision-making.
OECD & WHO (Health workforce constraints)
OECD/WHO (2022) Health at a Glance: Europe – Workforce and Capacity. Paris: OECD Publishing.
Provides the macroeconomic justification for treating workforce impact as a first-order decision variable.